Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
|Articles|February 1, 2016
- Pharmaceutical Technology-02-01-2016
- Volume 2016 Supplement
- Issue 1
Pharmaceutical Technology, 2016 Partnerships in Outsourcing Supplement (PDF)
Click the title above to open the Pharmaceutical Technology 2016 Partnerships in Outsourcing Supplement in an interactive PDF format.
Advertisement
Articles in this issue
almost 11 years ago
Success Story: Transferring a Phytochemical API Portfolioalmost 11 years ago
The Impact of SEND on the Pharmaceutical Industryalmost 11 years ago
Under New Ownership: Consolidation Reshapes Contract Services Marketalmost 11 years ago
Quality Metrics and Best Practices for Working with Contract Labsalmost 11 years ago
Lab Services: To Outsource or Not to Outsourcealmost 11 years ago
Keeping It Simple: Collaborating for Success in Drug Deliveryalmost 11 years ago
Preventing Phase III Failuresalmost 11 years ago
Surveys Examine Outsourcing Trendalmost 11 years ago
Emerging Life-Sciences Markets: New Partnerships, New Competitorsalmost 11 years ago
UV Spectroscopy Gains Use in Dissolution TestingAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
4
Our Biggest Takeaways From AAPS PharmSci 360
5